Results from the second Multicenter Selective Lymphadenectomy Trial, which were published in 2017, confirmed that immediate CLND in patients with metastases found on SLNB increases the rate of regional disease control and provides prognostic information. However, no increase in melanoma-specific survival after immediate CLND were noted.
In that same trial, CLND increased the risk for lymphedema, occurring in 24.1% of the dissection group versus 6.3% of the observation group (P < .001). However, in the majority of cases (64%), lymphedema was mild, whereas it was moderate in 33% of cases and severe in 3%.
Learn more about regional lymph node dissection in patients with melanoma.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Chih-Shan Jason Chen. Fast Five Quiz: Melanoma Treatment - Medscape - Jan 24, 2020.